Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Sales

Burning Rock Biotech (BNR) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to 13.97%.

  • Burning Rock Biotech's EBITDA Margin rose 2064.00% to 13.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.15%, marking a year-over-year increase of 6515.00%. This contributed to the annual value of 66.53% for FY2024, which is 5432.00% up from last year.
  • Latest data reveals that Burning Rock Biotech reported EBITDA Margin of 13.97% as of Q3 2025, which was down 107.51% from 6.73% recorded in Q2 2025.
  • Burning Rock Biotech's EBITDA Margin's 5-year high stood at 6.73% during Q2 2025, with a 5-year trough of 195.13% in Q1 2022.
  • In the last 3 years, Burning Rock Biotech's EBITDA Margin had a median value of 76.45% in 2023 and averaged 71.23%.
  • As far as peak fluctuations go, Burning Rock Biotech's EBITDA Margin surged by 12,465bps in 2021, and later crashed by 4,757bps in 2022.
  • Burning Rock Biotech's EBITDA Margin (MRQ) stood at 186.42% in 2021, then rose by 16bps to 157.17% in 2022, then grew by 14bps to 134.75% in 2023, then surged by 57bps to 58.47% in 2024, then surged by 76bps to 13.97% in 2025.
  • Its EBITDA Margin stands at 13.97% for Q3 2025, versus 6.73% for Q2 2025 and 10.21% for Q1 2025.